Financial Calendar

Interim report 2nd quarter 2021, August 19

Interim report 3rd quarter 2021, November 25

MEET US AT

Bio International Digital, June 14-18 2021 https://www.bio.org/events/bio-digital

Bio Europe, Stockholm, October 25-27 2021, https://informaconnect.com/bioeurope/

JP Morgan San Francisco January 10-13 2022, https://www.jpmorgan.com/solutions/cib/insights/health-care-conference

Asarina Pharma AB
Registered office in Solna, Sweden
Reg no 556698-0750
© All rights reserved

Navigation

Home
Science
Sepranolone
Menstrual Migraine
Tourette Syndrome
PMDD
Investors
Press Releases
About Us
Contact

Contact

Asarina Pharma AB
Karolinska Institutet Science Park
Fogdevreten 2
SE – 171 65 Solna, Sweden

About Asarina Pharma

Asarina Pharma is a Swedish biotech company developing Sepranolone for Allopregnanolone-related stress, compulsion, menstrual and neurological disorders. Our product pipeline is built on over 40 years of research into llopregnanolone-related neurological disorders. With our new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) we aim to deliver a new generation of efficacious and safe drugs for still widely untreated neuroendocrinological conditions.

This site uses cookies. By continuing to use this website you agree to our use of cookies. Accept
Read more about how we use cookies here. Read More

Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

SAVE & ACCEPT